PT Kalbe Farma Tbk. (IDX:KLBF)

Market Cap	33.03T -52.9%
Revenue (ttm)	36.21T +9.6%
Net Income	3.62T +7.7%
EPS	79.64 +9.1%
Shares Out	45.25B
PE Ratio	9.17
Forward PE	8.89
Dividend	36.00 (4.97%)
Ex-Dividend Date	Jun 4, 2026

Volume	154,609,000
Open	735.00
Previous Close	730.00
Day's Range	700.00 - 735.00
52-Week Range	630.00 - 1,560.00
Beta	-0.04
Analysts	Strong Buy
Price Target	1,316.47 (+86.73%)
Earnings Date	Jul 31, 2026

About PT Kalbe Farma Tbk.

PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business, and E-health products. In addition, the company provides health screening services; operates as ...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1966
• Employees: 12,895
• Stock Exchange: Indonesia Stock Exchange
• Ticker Symbol: KLBF

Financial Performance

In 2025, PT Kalbe Farma Tbk.'s revenue was 35.32 trillion, an increase of 8.27% compared to the previous year's 32.63 trillion. Earnings were 3.66 trillion, an increase of 13.09%.

Analyst Summary

According to 18 analysts, the average rating for KLBF stock is "Strong Buy." The 12-month stock price target is Rp 1,316, which is an increase of 86.73% from the latest price.

Price Target

Rp 1,316

(86.73% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 15, 2026

Data Sources Report a data error